종근당홀딩스

001630KOSPI의약품 제조업

61.0 / 100

Reference Date: 2026-04-13

Financial Score30.0 / 40

News Sentiment15.0 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue metrics are weak. Slightly down 4.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JonggeunDang Holdings became a holding company through a corporate split in 2013, owning key subsidiaries such as JonggeunDang, Kyungbo Pharmaceuticals, and JonggeunDang Bio. Its primary revenue streams include management fees, brand usage fees, and dividends, with a strategy focused on specialized business areas to enhance corporate and shareholder value. Major subsidiaries operate in diverse sectors like raw pharmaceutical materials, finished drugs, and health functional foods.

Number of Employees

38people

Average Salary

143.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.60Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.26Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

6.16Industry Average 4.424.0Point

In line with industry avg

Debt Ratio

10.95Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲86.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 5.3% (improving, 3yr)

Detailed News Sentiment

10 totalPositive 2Neutral 5Negative 0Average Sentiment Score 64.3

Positive
경보제약, 아산공장 美 FDA 현장 실사 통과
종근당홀딩스 자회사 경보제약이 아산공장의 미국 FDA 현장 실사를 통과하여 미국 시장 진출에 청신호가 켜졌습니다.
Positive
종근당 계열 경보제약, 아산공장 美 FDA 현장 실사 통과
종근당홀딩스 자회사 경보제약이 미국 FDA 현장 실사에서 VAI 판정을 받아 실사를 통과했습니다.
Neutral
한미약품, 첫 외부 대표 내정…"최대주주 영향력 확대"
한미약품이 첫 외부 대표를 내정하고 최대주주의 영향력이 확대되었다는 소식은 종근당홀딩스와 직접적인 관련이 없습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (32%)

Current 47,600Won52-week high 56,40052-week low 43,300

1-month return2.0Point

1m -4.80% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral단일판매ㆍ공급계약해지(자회사의 주요경영사항)2026-04-10
Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral주식등의대량보유상황보고서(일반)2026-03-23